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Objective:Bradykinesia is one of the clinical hallmarks of Parkinson’s disease (PD) and atyp-
ical Parkinsonian syndromes. Clinical ratings scales and technology-based assessments
have been developed to measure bradykinesia. We review the different tools that exist
for measurement of bradykinesia and analyze their reliability and applicability to PD and
atypical Parkinsonian syndromes.
Methods: We summarize data on the factor structure of the two primary scales used to
assess PD, the Unified Parkinson’s Disease Rating Scale (UPDRS) and Movement Disor-
der Society revision of the UPDRS, the MDS-UPDRS. We review how these scales have
been used in atypical Parkinsonian syndromes, specifically Progressive Supranuclear Palsy
(PSP). Finally, we report on the different technology-based tools being used to assess
bradykinesia.
Results: The UPDRS is a useful measure of PD function and disability with six clinically
distinct factors, three of which pertain to bradykinesia. The MDS-UPDRS has shown high
internal consistency and correlation with the original UPDRS. Factor analysis of the UPDRS
in PSP reveals five clinically distinct factors, two of which are independent bradykinesia
factors.Thus the UPDRS and MDS-UPDRS are reliable and applicable scales for PD and the
UPDRS can be used to assess bradykinesia in PSP. Technology-based tools for measuring
bradykinesia include gyrosensors, Coordination Ability Test System, Brain Test, quantita-
tive digitography, Motus motion analysis system, precision real-time image-based motion
analysis, and the At-HomeTesting Device.These tools have been compared to the UPDRS
motor subscale and are effective in assessing bradykinesia.
Conclusion:The UPDRS and MDS-UPDRS are well-established measures of bradykinesia
that are applicable and useful in PD. The UPDRS is also been shown to be applicable to
PSP. Different technologies exist to measure bradykinesia, though further work is needed
to validate these assessment tools and bring them to clinical practice.
Keywords: bradykinesia, UPDRS, MDS-UPDRS, technology, Parkinson disease, PSP
INTRODUCTION
Bradykinesia is one of the clinical hallmarks of Parkinson’s disease
(PD) and atypical Parkinsonian syndromes and can be measured
with clinical tools in the form of rating scales, as well as technology-
based assessments. These different tools are complementary and
can be utilized separately or together, depending on the assessment
goals.
CLINICAL RATING SCALES
Clinical rating scales are instruments that provide a numeric
value to clinical signs considered pertinent to the assessment
of a given condition. In PD, a number of scales were devel-
oped prior to 1980, including the Columbia University Rating
Scale (CURS), the Webster Scale, and the Parkinson’s Disease
Impairment Scale (PDIS) (Ramaker et al., 2002). These scales
evaluated bradykinesia, combining slowness, hesitation, break-
down of smooth movement, and amplitude decrements into a
combined assessment that was ranked from normal (0) to the
highest allowable score for severe bradykinesia, meaning unable
or barely able to execute a given motor task. To cull the most
important features of PD from these different scales, an effort to
develop scales using the designation “Unified” evolved with two
key scales, the Unified Parkinson’s Disease Rating Scale (UPDRS)
and its recent update, the Movement Disorder Society revision
of the UPDRS (MDS-UPDRS). An additional scale, the Mod-
ified Bradykinesia Rating Scale for PD (Heldman et al., 2011)
has also been used in clinical practice, though the gold stan-
dard for assessment of bradykinesia remain the UPDRS and the
MDS-UPDRS.
THE UNIFIED PARKINSON’S DISEASE RATING SCALE
The UPDRS was developed to assess PD function, and bradyki-
nesia is rated by observation of several tasks, each scored using
five options from normal (0) to severe impairment (4). Eleven of
the total 27 objective ratings measure bradykinesia through fin-
ger taps, hand movements, rapid alternating movements of the
hands, leg agility, arising from a chair, gait, and body bradykinesia
and hypokinesia. The factor structure and internal consistency has
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been studied in 294 PD patients in the “on” state, that is during
the period of the day when they experience positive dopaminer-
gic medication effects. Factor structure analysis was performed
and six factors were obtained which accounted for approximately
78% of the sample variance. Three of these six factors concerned
bradykinesia. Items assessing axial function, balance, and gait clus-
tered together into one factor. Two additional distinct factors, right
side extremity and left side extremity bradykinesia were also iden-
tified. There was no correlation between bradykinesia testing on
the right and left sides. These UPDRS measures of bradykinesia
correlated well with other measures of PD disability, i.e., Hoehn
and Yahr (HY) staging and Schwab and England ADL scale (SE)
(Stebbins and Goetz, 1998).
In order to confirm that the statistic stability of the UPDRS fac-
tor structure across different groups of patients with varying levels
of PD impairment, a subsequent analysis was performed with PD
patients in the off state, that is when medication effects were not
apparent. In a sample of 200 patients examined in the off state,
with identical analytic methods used in the prior publication, six
factors were again identified and accounted for approximately 70%
of the variance, three of which related to bradykinesia. All assess-
ments of axial function, speech, facial expression, balance, and gait
clustered together into one factor. Again, two additional distinct
factors assessing bradykinesia affecting the extremities were identi-
fied, right and left. There was no correlation between bradykinesia
testing on the right and left sides. There was a significant relation-
ship between the individual factors assessing bradykinesia from
the UPDRS and the HY stage. The results were highly consistent
between the two studies, confirming the reliability and validity of
the UPDRS as a scale for assessment of bradykinesia in PD both
when patients are experiencing medication benefit and when they
are not (Stebbins et al., 1999).
The UPDRS has also been applied to the evaluation of parkin-
sonian syndromes outside of PD. Progressive Supranuclear Palsy
(PSP) shares some clinical features with PD and is the most com-
mon and best recognized condition among the atypical parkinson-
ian syndromes. A study analyzing the factor structure of UPDRS
Motor Examination in 175 PSP patients revealed five factors which
accounted for approximately 64% of the sample variance, two of
which assess bradykinesia. Items assessing axial bradykinesia and
gait clustered into one factor, and items assessing bradykinesia of
the extremities, right and left combined, clustered into a sepa-
rate factor. There was no correlation between these two factors,
and each of the factors assessing bradykinesia was significantly
related to HY stage. No side-to-side difference in bradykinesia
was found in the factor analysis for PSP patients, which follows
the typical clinical presentation of PSP as a symmetrical illness in
contrast with the asymmetry of typical PD. These results support
the validity and reliability for the use of the motor scale of the
UPDRS in measuring bradykinesia for patients with PSP (Cubo
et al., 2000).
THE MOVEMENT DISORDER SOCIETY-SPONSORED REVISION OF THE
UNIFIED PARKINSON’S DISEASE RATING SCALE
The MDS-UPDRS is a revision of the original UPDRS, aimed at
retaining the strengths of the original scale and resolving some of
the ambiguities and identified weaknesses. In regards to bradyki-
nesia, the main addition to the MDS-UPDRS involves toe tapping.
Conceptually, the UPDRS and the MDS-UPDRS are not iden-
tical, as the new scale was designed specifically to detect very
mild changes not captured in the original scale. As such, the
five options for each item are “normal,” “slight,” “mild,” “mod-
erate,” and “severe” impairment whereas the original scale focused
more on advanced disease. Thus for most items, and specifi-
cally the bradykinesia items, direct item-to-item mapping is not
possible between the two scales. The factor structure of the MDS-
UPDRS was evaluated in a study of 877 native English-speaking
PD patients of diverse race/ethnicity representations. Exploratory
and confirmatory analysis of the individual parts of the MDS-
UPDRS identified a factor structure that was statistically consistent
and clinically meaningful for all parts. Eigenvalues and scree plots
informed the exploratory factor analysis which determined the
number of factors that best represented the data. Confirmatory
analysis was used to assess dimensionality, with a comparative fit
index (CFI) greater than or equal to 0.90 as an acceptable fit. For
the Motor Examination the CFI= 0.91, and seven factors were
identified, four of which pertained to bradykinesia (midline func-
tion, bradykinesia right upper extremity, bradykinesia left upper
extremity, lower limb bradykinesia, including both right and left
legs). Further, there was a strong concurrent validity based on
high correlations between the MDS-UPDRS and the UPDRS Part
III (r = 0.96). These results support the reliability and validity of
the MDS-UPDRS in PD patients. This has led to an increasing
trend in the field to adopt this newer scale as the “gold standard”
(Goetz et al., 2008).
TECHNOLOGY-BASED TOOLS
Although clinical rating scale scores are based on objective face-
to-face examination of a patient, clinical judgment, and some
degree of subjectivity are involved. Further, the limited item scor-
ing options do not provide a wide array of choices with continuous
variables. To help quantify bradykinesia more objectively, a vari-
ety of different technology-based tools have been developed. These
technology-based tools were correlated with clinical examination
scores from the UPDRS and/or the MDS-UPDRS to assess validity
and reliability, since clinical scales are the gold standard for most
researchers and regulatory agencies. We performed a search of
PubMed.gov and included articles published since the year 2000.
Specific tools where the authors made a correlation between the
standard clinical examination tools, (i.e., elements of the UPDRS
and/or the MDS-UPDRS) and the technology-based assessments
are discussed below.
GYROSENSORS
The gyrosensor measures angular movement in terms of angular
velocity and limits gravitational artifact. This sensor was used to
assess bradykinesia during finger taps in 40 patients with PD and
14 age-matched control subjects. There were four performance
indices that were derived from the sensor signal – root-mean-
squared (RMS) angular velocity, RMS angle, peak power, and total
power. RMS velocity and RMS angle were expected to represent
slowing of finger-tapping motion and reduction in amplitude
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due to bradykinesia, respectively. Peak power and total power
were expected to represent the intensity of the main movement
component of finger tapping and the total intensity of move-
ment. There was moderate correlation (r = 0.73–0.80, P < 0.001)
between these performance indices and the clinical finger tap score.
Each of the different performance indices was able to differentiate
patients from controls (P < 0.001). Cronbach’s alpha was 0.85
and the intraclass coefficient was 0.74, showing a high inter-rater
reliability of the FT score (Kim et al., 2011).
BRAIN TEST
A computer software program (BRAIN TEST©), which is also
based on the finger-tapping test, has been used to assess bradykine-
sia. Subjects are instructed to tap marked standardized keyboard
keys successively for 60 s with their index finger as fast and as
accurately as possible. A Kinesia score (KS) is obtained which cor-
responds with the total number of keystrokes per 60 s, is used
as a measure of bradykinesia. To exclude inter-rater variabil-
ity, the same neurologist graded all cases. In 154 PD patients,
there was a significant correlation between KS and the UPDRS
Part III (r =−0.600, P < 0.001). Seventy-three PD patients were
also compared with age-matched control subjects and the PD
patients different significantly with regard to KS (70.3± 27.3 key-
strokes/min vs. 126.0± 21.7 keystrokes/min, t = 13.6; P < 0.001).
Based on KS and other measures, correct classification into the
control or Parkinson group was achieved in 85.6% of subjects,
showing this is a valid measure of bradykinesia (Homann et al.,
2000).
COORDINATION ABILITY TEST SYSTEM
Another tool that has been used to quantify bradykinesia is
the Coordination Ability Test System (CATSYS). In a study of
44 patients with PD, this device was used to assess bradykine-
sia, specifically measuring tasks assessed in the UPDRS, prona-
tion/supination and finger tapping using a touch sensitive record-
ing plate. Using this system, bradykinesia was assessed and mea-
sures were compared to corresponding UPDRS items. There was
a significant correlation of the mean value for CATSYS prona-
tion/supination with the corresponding UPDRS item (ρ=−0.411,
P < 0.014), but there was no relationship with CATSYS finger-
tapping values with the corresponding UPDRS bradykinesia items
(P > 0.05). Though the CATSYS was reliable in discriminating
between PD and control subjects, it did not clearly show validity
compared to the UPDRS (Papapetropoulos et al., 2010).
QUANTITATIVE DIGITOGRAPHY
A musical instrument digital interface (MIDI) keyboard has been
used to assess bradykinesia in a technique termed quantitative dig-
itography (QDG). For each finger, the means of key-strike velocity,
duration of finger strike, and the interval between strikes were cal-
culated during a repetitive alternating finger-tapping task (RAFT)
over 30 s. In 33 patients who were off PD medications, QDG scores
were correlated with the UPDRS part III scores, specifically with
the CV duration of finger strike (r = 0.66; P < 0.001), key-strike
velocity (r =−0.61;P < 0.001),and the CV of the interval between
strikes (r = 0.56; P < 0.001). A model combining three QDG vari-
ables, key-strike velocity (Vel), interval between strikes (Int), and
the CV of the duration of the finger strike (CVDur) together best
predicted the UPDRS III scores (r = 0.704; P = 0.001). QDG was
compared to the UPDRS III to assess effects of therapy (medication
and STN DBS) on motor disability. Both the UPDRS and QDG
measurements are sensitive to improvements of overall and fine
motor control from medication and DBS, indicating its validity
and reliability. Interestingly, QDG was able determine a significant
difference in the effect of the two different therapies (medication
vs. DBS), that was not detectable using the UPDRS (Taylor Tavares
et al., 2005).
MOTUS MOTION ANALYSIS SYSTEM
Technology-based tools have been used in other aspects of the
surgical arena. Anecdotal reports suggested that patients’ motor
symptoms improve immediately following the STN DBS surgi-
cal procedure prior to pulse generator activation, a phenome-
non termed the “microlesion” effect. A quantitative measure of
bradykinesia, root mean square velocity of angular movement
(Vrms), was used to formally study this concept during a quanti-
tative repetitive wrist pronation-supination (qrWPS) task using
the Motus motion analysis system in 101 patients. Measures
of bradykinesia were collected at three time points during the
STN DBS procedure: pre-MER (microelectrode recording), post-
MER, and during high-frequency electrical stimulation from the
quadripolar electrode. Patients were assessed preoperatively in the
off medication condition and the Vrms value showed an inverse
correlation with a UDPRS Motor Examination bradykinesia sub-
score (Spearman rank correlation, r =−0.54; P = 0.001; n= 61).
Higher angular velocity indicated less limb bradykinesia and val-
idated Vrms as a measure of bradykinesia. Using this technology,
patients Vrms scores improved by 28.0% (P < 0.003) between pre-
and post-MER, and 41.0% (P < 0.003) between post-MER and
intraoperative DBS (Koop et al., 2006).
PRECISION REAL-TIME IMAGE-BASED MOTION ANALYSIS
Variations of the finger-tapping movement have also been stud-
ied using technology-based tools using wire free contact sensors.
This technology, called Precision Real-time Image-based Motion
Analysis (PRIMAS) has been used to develop a novel parameter, a
finger-tapping test score (FTTS), to rate the finger-tapping move-
ment. The FTTS for each Parkinsonian patient was found to be
smaller than the average for healthy subjects. This was also true
for Parkinsonian patients who were HY stage I, illustrating that
this technology could be used to distinguish patients with early
disease from healthy subjects. However, the reliability of the test
among subjects was variable, and improved with repeated testing,
indicating the presence of a learning effect. Also, though finger
tapping is a part of the motor subscore of the UPDRS, the inves-
tigators did not evaluate the validity of this tool compared to the
actual UPDRS scale (Jobbágy et al., 2005).
AT-HOME TESTING DEVICE
Since most long-term clinical trials assess the UPDRS scores at
baseline and at fixed time intervals, a tool was developed which
would measure changes more frequently and at home, termed the
At-Home Testing Device (AHTD). To assess bradykinesia, patients
performed a series of motor tasks using a computer module and
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the data obtained could be electronically transmitted to a central
computer bank, which was found to be technically reliable. In a
study of 50 untreated PD patients with less than 5 years of dis-
ease, the mean monthly change of the AHTD data was compared
with changes in office-based UPDRS scores at 3 and 6 months.
The AHTD measured bradykinesia through alternating finger tap-
ping (digitography) and hand tapping. Over the 6-month period,
patients declined in overall UPDRS motor function (P = 0.009)
but measures of AHTD bradykinesia did not detect changes ear-
lier or more robustly than the clinical scales, indicating this is
not a valid tool for assessment of bradykinesia (Goetz et al.,
2009).
DISCUSSION
Bradykinesia, one of the hallmarks of PD is effectively measured by
the UPDRS and the MDS-UPDRS, and the clinical exam remains
the gold standard for evaluation of Parkinsonian patients. These
scales have also been effectively applied to atypical Parkinsonian
syndromes such as PSP. Additional scales such as the Modified
Bradykinesia Rating Scale have also been developed and are being
used in both in patient and clinical trials. However, the UPDRS
and the MDS-UPDRS remain the most widely accepted scales.
Technology-based tools are aimed at quantifying bradykinesia
objectively to increase diagnostic accuracy and to help monitor
subtle clinical changes when therapies are initiated. To date, no
new treatment has received regulatory approval based on use of
technology-based objective measures of bradykinesia or any other
objective measure of parkinsonism.
There remains a role and need for technology-based tools,
and this need may grow with further research. Although both
the UPDRS and MDS-UPDRS have good inter-rater reliability,
some variation exists among different raters evaluating the same
subject. Technology-based tools such as the gyrosensor have the
potential to reduce the inter-rater variability of clinical scales. Also,
technology-based tools may be useful in measuring the effects of
therapies on motor function that may be subtle in early stages
of PD as was shown with QDG and PRIMAS. The UPDRS and
MDS-UPDRS may assign the same summary score to patients with
different aspects of impairment. For example, a finger-tapping
score is based on of “2” is given to three possible attributes:
slowness, fatiguing, and arrested movement. A patient who can
maintain the rhythm of the task but does the movements slowly is
given the same score as a patient who can perform the repetitions
faster, but with freezes or hesitations in movement. Quantitative
analysis with tools such as QDG may help parse out these differ-
ences, and may be a more sensitive method of assessing a patient’s
unique motor profile so that it can be accurately tracked over time
(Bronte-Stewart et al., 2000). Tools such as Motus and QDG are
already being used in surgical evaluation of DBS patients where
quantitative measures of bradykinesia help to shed light on the
pathophysiology and effects of DBS that are not discerned by a
clinical rating scale. However, there are also limitations to cer-
tain tools, as noted with Brain Test©. Also, the availability of the
technology-based tools as discussed above is currently limited,
although greater commercial and research-based availability can
be envisioned for the future.
The practicality of technology-based rating measures still needs
to be established. Though bulky and expensive equipment will
never be widely adopted, the new availability of I-Pads and I-
Phones suggests that easy to use measures might allow very fre-
quent and home-based documentation more linked to daily living
than the forced protocols of office examinations. Technology-
based tools need to be validated with larger patient populations
crossing the gamut of parkinsonian disabilities. Further, norma-
tive data on the tool that is being developed is critical so that
the patient population with disease can be appropriately assessed.
The tool being assessed should also be studied over an appropriate
time span. The UPDRS and MDS-UPDRS are typically assessed
at 3- or 6-month intervals in clinical trials and these scales are
sensitive enough to detect changes in motor decline within this
time period. In contrast, the ATHD was not able to detect clinical
worsening of bradykinesia that was evident on the UPDRS. Thus
the tool being developed must be valid not only in discriminat-
ing between patients with disease compared to control subjects,
but must also be able to detect changes over standard intervals
of time. Also, we are already seeing improvements from a tech-
nological perspective. Heldman et al. (2011) used motion sensors
to assess bradykinesia to measure the reliability of the Modified
Bradykinesia Rating Scale and compared it with the UPDRS. They
were able to find that the MBRS was reliable as compared to the
UPDRS, and were also able to correlate the MBRS data with the
kinematic measures obtained from the motion sensors. Mera et al.
(2012) have taken this a step further and developed a home-based
automated method based on these motion sensors that can be used
for assessment of PD that measures both tremor and bradykinesia.
The disease progression as measured by clinical tools is often non-
linear, whereas the amount of data generated by technology-based
tools may be sensitive enough to capture the slowly progressive
decline in Parkinsonian disorders. However, the decline in PD is
not necessarily linear and certainly can be variable from patient to
patient, so such technology-based tools may be helpful in assess-
ing the trajectory of disease progression in different patients. The
prospects for increasingly simple and valid measurement tools
are high.
Additional cautionary caveats need to be emphasized as these
tools are developed. First, the numbers generated must have a
direct bearing on the clinical state under question, because an
improvement in a movement variable, even if statistically sig-
nificant, has little importance if it does not correlate strongly
with clinically appreciated improvements. Further, such tools have
the potential to register almost limitless information and over-
sampling can lead to data sets difficult to interpret. As in the case
of the BRAIN TEST© software, the learning effects need to be con-
sidered, as well as confounding influences of cognitive function,
motivation, tremor, and the topographic distribution of the motor
deficit being measured. As such, rating scales and technology-
based tools s are likely to be used in research and clinical care
as complementary strategies for tracking disease progression and
response to treatment. Private technology firms, pharmacologic
industry,PD foundations, and governments are increasingly vested
in accurate measurement of PD, so it is likely that rapid advances
in bradykinesia monitoring will be achieved.
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